血清CA125、NSE、CYFRA21—1及SCCA聯(lián)合檢測(cè)對(duì)肺癌的診斷價(jià)值研究
發(fā)布時(shí)間:2018-06-23 來源: 美文摘抄 點(diǎn)擊:
【摘要】 目的 探討血清糖類抗原125(CA125)、神經(jīng)元特異性烯醇化酶(NSE)、細(xì)胞角蛋白19片段(CYFRA21-1)及鱗狀小細(xì)胞癌抗原(SCCA)聯(lián)合檢測(cè)對(duì)肺癌的診斷價(jià)值。方法 選取72例肺癌患者作為觀察組(小細(xì)胞癌20例, 鱗癌36例, 腺癌16例), 另選取72例健康人作為常規(guī)組。兩組均進(jìn)行血清CA125、NSE、CYFRA21-1及SCCA檢測(cè)。觀察比較兩組的CA125、NSE、CYFRA21-1、SCCA水平及其陽性率。結(jié)果 觀察組小細(xì)胞癌、鱗癌、腺癌患者的CA125、NSE、CYFRA21-1、SCCA水平均高于常規(guī)組, 差異均具有統(tǒng)計(jì)學(xué)意義(P<0.05)。觀察組患者CA125、NSE、CYFRA21-1、SCCA的陽性率分別為58.33%、69.44%、88.89%、83.33%, 均高于常規(guī)組的0、0、0、0, 差異均具有統(tǒng)計(jì)學(xué)意義(P<0.05)。
結(jié)論 血清CA125、NSE、CYFRA21-1、SCCA聯(lián)合檢測(cè)對(duì)肺癌診斷價(jià)值較高, 可以對(duì)肺癌進(jìn)行鑒別診斷、分析癌癥類型以及病情嚴(yán)重程度, 有助于醫(yī)師開展針對(duì)性治療, 從而改善患者預(yù)后。
【關(guān)鍵詞】 糖類抗原125;神經(jīng)元特異性烯醇化酶;細(xì)胞角蛋白19片段;鱗狀小細(xì)胞癌抗原;
肺癌
DOI:10.14163/j.cnki.11-5547/r.2018.12.001
【Abstract】 Objective To discuss the diagnostic value of combined detection of serum carbohydrate antigen 125 (CA125), neuron specific enolase (NSE), cytokeratin 19 fragment (CYFRA21-1) and squamous cell carcinoma antigen (SCCA) in lung cancer. Methods There were 72 lung cancer patients as observation group (20 cases of small cell carcinoma, 36 cases of squamous cell carcinoma and 16 cases of adenocarcinoma), and
72 healthy people as routine group. Serum CA125, NSE, CYFRA21-1 and SCCA were detected in all two groups. The levels of CA125, NSE, CYFRA21-1 and SCCA and their positive rates were observed and compared in the two groups. Results The observation group had higher CA125, NSE, CYFRA21-1 and SCCA level in small cell carcinoma, squamous cell carcinoma and adenocarcinoma cases than routine group, and their difference was statistically significant (P<0.05). The observation group had positive rate of CA125, NSE, CYFRA21-1 and SCCA respectively as 58.33%, 69.44%, 88.89% and 83.33%, which were all higher than 0, 0 , 0 and 0 in the routine group, and their difference was statistically significant (P<0.05). Conclusion Combined detection of serum CA125, NSE, CYFRA21-1 and SCCA shows high diagnostic value for lung cancer, and it can identify the lung cancer, analyze the type of cancer and the severity of the disease, which is helpful for doctors to carry out targeted treatment and improve the prognosis of patients.
【Key words】 Carbohydrate antigen 125; Neuron specific enolase; Cytokeratin 19 fragment; Squamous cell carcinoma antigen; Lung cancer
肺癌是我國(guó)高發(fā)癌癥之一, 在臨床中屬于惡性腫瘤, 根據(jù)臨床數(shù)據(jù)得知, 男性肺癌的發(fā)生率高于女性, 這多與男性吸煙、喝酒有所關(guān)聯(lián)。肺癌初期臨床不明顯, 當(dāng)確診疾病時(shí)多為中晚期[1]。在臨床中, 確診肺癌相關(guān)指標(biāo)有血清CA125、NSE、CYFRA21-1及SCCA。因此, 本文就針對(duì)血清CA125、NSE、CYFRA21-1及SCCA聯(lián)合檢測(cè)對(duì)肺癌的診斷作用進(jìn)行分析, 現(xiàn)報(bào)告如下。
1 資料與方法
1. 1 一般資料 選取本院2016年11月~2017年11月收治的72例肺癌患者作為觀察組, 抽選同期72例健康人作為常規(guī)組。常規(guī)組: 男48例, 女24例;年齡32~72歲, 平均年齡(49.32±7.56)歲。觀察組:男44例, 女28例;年齡33~73歲, 平均年齡(50.44±7.52)歲;疾病類型:小細(xì)胞癌20例, 鱗癌36例, 腺癌16例。兩組性別、年齡等一般資料比較差異均無統(tǒng)計(jì)學(xué)意義(P>0.05), 具有可比性。
相關(guān)熱詞搜索:血清 肺癌 診斷 檢測(cè) 價(jià)值
熱點(diǎn)文章閱讀